Countries In Asia-Pacific Research Articles

Application Of The Health Belief Model In Improving Healthy Behaviors Among Pregnant Women: A Literature Review

Introduction: Maternal mortality rates around the world are still high. The first place out of 25 countries in Asia Pacific is Salomon Island with 327 per 100,000 live births, while the sustainable development goal target in 2030 is 70 per 100,000 live births. Factors influencing the high maternal mortality rate are pregnancy complications, demographics, sanitation, maternal education, and husband's education. Knowledge deficits require intervention in order to change behavior with appropriate approaches, such as the HBM (Health Belief Model). Objective: to determine changes in health behavior with the application of the Health Belief Model among pregnant women. Methods: This study used a literature review design. The databases involved in the search are Scopus, PubMed, Web of Science, Embase, and Google Scholar. Inclusion criteria: research with the topic Health Belief Model in Pregnancy, publication 2018-2023, full text Mesh terms used: health belief model AND pregnant women OR pregnancy. Result: Database extraction results obtained (n = 8) articles from 235 articles. Educational or evaluation materials that use Health Belief Model were nutrition education, prevention of anemia, preeclampsia, gestational diabetes, influenza vaccination, prevention of urinary tract infections, and acceptance of the COVID-19 vaccination. Conclusions: This review demonstrates the lack of evidence-based research to apply Health Belief Model to pregnant women. Nurses need to apply the concept of health belief model to pregnant women in future research and education.

Proposed Knowledge Management Strategy by Leveraging Current Technology to Increase Productivity Operation in PT. Trimata Benua

As coal industries is still attractive in the world, and a significant contributor for energy production which account approximately 37% for electricity generation. This type of fossil fuel is still being used by many countries despite it negative side effect to environment for example a greenhouse gas emission. Coal attractiveness is due to the fact that it is cheaper compared to other fossil fuel, resulting coal industries is still growing and predicted for many years to come. In Asia Pacific there are many countries dubbed as largest producers of coal, with China, India, and Indonesia being on the top three countries in Asia Pacific. With expected growth of 3.5% on yearly basis this makes Asia Pacific a significant contributor of the worlds coal industry. With that as well Asia Pacific contributes around 52% of the worlds carbon emissions in year 2020. Indonesia as the third largest coal producers, have approximately 8.9% growth in 2021. With projected coal production of 2.6% Year on Year. PT. Trimata Benua is one of the key players in Indonesia’s coal production. However, the company experience lack of productivity in operations, causing their production target missed. Is the absence of knowledge management system in the company causing that issue to arise. With that the company need to roll out and plan effective and structured knowledge management system to address their business issue. This research is based on three research questions. First one what is the best fit knowledge management strategy, second is to identify issues in operations, and the last one is to have suggestion for the company on the implementation plan based on their needs. This research will answer those research questions by referencing to the knowledge management theories on the People, Process, and Technology (PPT) as well as adopting Nonaka’s SECI model in knowledge transformation cycle and Jann model knowledge management framework (Jann). Since this research is the first stage of implementing knowledge management system, it will be a qualitative method used with data collection gathered through interviews. Data will be analyse using thematic analysis. There are several issues identified in relation of People, Process, and Technology. Ranging of the lack of professionalism, incomplete SOP, awareness and training program, and the minimum technology that is supporting operation team causing the inability of easy access to knowledge. By applying and utilize PPT, SECI, and as well as Jann framework, author manage to compile and design knowledge management system that is best fit for the company. Identifying the challenges, addressing capability gaps on the organization as well as identification of organization critical knowledge to achieve the objectives of implementation. This will be compiled into a plan in designing knowledge management system. With the implementation of the system, it will result enhancement for operation team to increase their productivity, enhance decision-making process that will benefit the company in the future and raised their competitiveness with their competitors. The implementation plan will begin in February 2024, and it will cover three enablers of KM people, process, and technology. Strengthen the implementation the organization will also create KM steering committee that will oversee, review, and manages the initiatives. The committee will also do the evaluation on the system in making sure that it is stay updated, measuring the impact, and identify necessary changes.

Production, Consumption, Export and Carbon Emission for Coal Commodities: Cases of Indonesia and Australia

The contribution of this study is to analyze the impact of a series of economic activities from the coal commodity on carbon emission. This research specifically focuses on coal exporting countries in Asia Pacific, including Indonesia and Australia during the period 2000 to 2022. The purpose of this study is to investigate the influence between production, consumption and export of coal and its determinants, and also the effect on carbon emission. This study applies the simultaneous equation approach and panel regression. The main findings of this study are that coal consumption, coal export, technological innovation and coal price have a positive and significant effect on coal production. Furthermore, coal production, domestic income and domestic investment have a positive and significant effect on coal consumption, while coal export has a negative and significant effect. Then, coal production and coal stock have a positive and significant effect on coal export, while coal consumption and domestic investment have a negative and significant effect. Finally, production, consumption and export of coal commodities contribute to increasing carbon emission. We recommend the coal exporting countries analyzed in this study to implement coal energy control in addressing increasing carbon emission at the global level.

Upscaling CCUS in Asia Pacific – a look at upstream synergy projects and potential for multi-user hubs

Carbon Capture, Utilisation and Sequestration (CCUS) has sustained its momentum as a key technology requirement for Asia Pacific countries to achieve reduced emissions and net-zero targets in the long term. Looking at the upstream E&P (Exploration & Production) industry and with gas being an integral part of the region’s energy mix, we are seeing companies assess integration of CCUS in key gas developments and take initial steps in creating multi-user storage hubs. Moving towards realising these projects however remains the main uncertainty with key legal, regulatory and fiscal incentive drivers required. International Oil Companies (IOCs), National Oil Companies (NOCs), independents and local companies are all participating, initiating partnerships and collaboration with other industries (for potential CO2 sources) towards integrated feasibility assessments and fast-track pilot projects. Focus CCUS projects between countries are also different, with a few leaning towards utilisation of CO2 through Enhanced Oil Recovery (EOR) and Enhanced Gas Recovery (EGR). Others look to establish more storage-related projects and hub creation. How each country has moved towards providing a solid regulatory framework and incentives to enable more commercial-scale CCUS projects is also different. This presentation will aim to: Compare CCUS projects, regulatory and incentive trends in Australia with those in key producing countries in Asia Pacific. Look at emissions reduction and economic impact of CCUS in gas projects and what factors will drive further implementation and upscaling. Provide perspective on hub potential for Australia and South East Asia. Compare and identify early successes, challenges and drivers in upcoming multi-user hub projects in Europe which we could learn from.

Determination of Natural Gas Consumption and Carbon Emission in Natural Gas Supplying Countries in Asia Pacific

This study investigates determination of natural gas consumption and carbon emission in the middle income group of natural gas supplying countries in Asia Pacific, including China, Indonesia, Malaysia, Myanmar and Vietnam during the period 2000-2021 by applying the simultaneous equation analysis. The results of this study are that carbon emission increase due to the real exchange rate, population and natural gas production, but carbon emission will reduce natural gas consumption. Furthermore, natural gas consumption increases due to natural gas production, GDP per capita and energy intensity. This study recommends the government to develop clean and efficient alternative energy to reduce carbon emission in response to natural gas demand for domestic and foreign market needs.

Optimalisasi Pembelajaran Jarak Jauh dalam Pelatihan UMKM untuk Peningkatan Kemampuan Pelaku UMKM di Era Ekonomi Digital

To prevent the virus transmission, Covid 19 Pandemic forced learning activities shifted from face to face to distance learning. Elements involved in the education and training of micro, small and medium enterprises, such as Education and Training institutions, teachers and participants are forced to adapt not only due to the pandemic but also to face the changing world economy into a digital economy due to the rapid evolution and increasing use of information and communication technology. communication. Indonesia is currently in 11 countries in Asia Pacific that use cellular operators that are experiencing rapid development in mobile collaborative platforms as an indicator of improving information and communication technology, especially in internet and cellular usage. For this reason, education and training institutions, teachers and participants are required to be able to take advantage of technological developments in the implementation of distance learning such as the use of the internet, Learning Management Systems and other supporting tools to support digital economic growth in Indonesia. This study aims to analyze and optimize the supporting factors for the development of Distance Learning related to the development of education and training during the pandemic.

Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study

BackgroundClinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking.MethodsPARACHUTE is a phase IV, prospective, non-interventional, observational study. Primary endpoint was the proportion of patients remaining progression free at 12 months. Secondary endpoints were ORR, PFS, safety and tolerability, and relative dose intensity (RDI).ResultsOverall, 190 patients with a median age of 61 years (range: 22.0–96.0) were included. Most patients were Asian (70%), clear-cell type RCC was the most common (81%), with a favourable (9%), intermediate (47%), poor (10%), and unknown (34%) MSKCC risk score. At the end of the observational period, 78 patients completed the observational period and 112 discontinued the study; 60% of patients had the starting dose at 800 mg. Median RDI was 82%, with 52% of patients receiving < 85%. Of the 145 evaluable patients, 56 (39%) remained progression free at 12 months, and the median PFS was 10 months (95% CI: 8.48–11.83). 19% of patients (21/109) were long-term responders (on pazopanib for ≥18 months). The best response per RECIST 1.1 was CR/PR in 24%, stable disease in 44%, and PD in 31%. Most frequent (> 10%) TEAEs related to pazopanib included diarrhoea (30%), palmar-plantar erythrodysesthesia syndrome (15%), and hypertension (14%).ConclusionsResults of the PARACHUTE study support the use of pazopanib in patients with advanced or mRCC who are naive to VEGF-TKI therapy. The safety profile is consistent with that previously reported by pivotal and real-world evidence studies.

Pengaruh Suku Bunga, Kurs Rill dan Pertumbuhan Ekonomi Terhadap Yield Obligasi Pemerintah: Lower Middel Income Countries di Asia Pasifik

This study explains the influence of monetary policy interest rates, real exchange rates and economic growth on government bond yields on Lower Middle Income Countries in Asia Pacific. This study combines cross section data in 5 countries with time series from 2007-2018, with the Panel Regression method and the Random Effect model selection test. The results show that: (1) Monetary Policy Interest Rates have a negative and significant effect on government bond yields on Lower Middle Income Countries in Asia Pacific, (2) The real exchange rate has a positive and insignificant effect on government bond yields for Lower Middle Income Countries in Asia Pacific. , (3) Economic growth has a negative and significant effect on government bond yields on Lower Middle Income Countries in Asia Pacific.

P647 Awareness, knowledge and use of mesenchymal stem cells – a global survey among gastroenterologists and colorectal surgeons

Abstract Background This study aimed to understand awareness, knowledge, and perception of mesenchymal stem cells (MSCs) among physicians, with particular focus on the complex perianal fistula (CPF) in Crohn’s disease (CD) indication. Methods A cross-sectional, web-based survey of currently practicing and registered gastroenterologists (GIs) and colorectal surgeons (CRs) across 15 countries in North America, Europe and Asia Pacific was undertaken. Descriptive analyses of data on awareness, knowledge, and perception of MSCs, willingness to use them in clinical practice and potential concerns were conducted overall and by medical specialty. Missing responses were allowed, thus denominators differed among questions (N values reported throughout). Multivariable logistic regression was used to examine factors associated with moderate/strong awareness of MSCs. Results Of 146 physicians, 115 (79%) were aware of MSCs (63% strong/moderate; 37% limited awareness), including 101 GIs (88%) and 14 CRs (12%). Of these, 21 physicians (19%, N=112) had treated ≥1 patient with MSCs. Among the aware physicians, the majority were moderately/largely interested in MSCs (87%, N=113), were willing to use them for patients with CD and CPF (82%, N=108) and believed MSCs address an unmet need for these patients (93%, N=101). However, there was a marked heterogeneity as to the assumed definition and mechanism of action (MoA) of MSCs (Figure 1). By specialty group, more CRs (50%) than GIs (31%) defined correctly MSCs as an immunomodulatory therapy. The majority of the physicians aware of MSCs stated that they have limited/no knowledge of this therapy (64%), its efficacy (51%), safety (53%) and MoA (65%) in patients with CPF in CD (N=105 for all questions). Many physicians (46%; N=107) also expressed concerns about using MSCs in these patients. In physicians with concerns, long-term efficacy, long-term safety, and cost were the most frequently reported concerns, both overall (Figure 2) and by each specialty group (data not shown). The multivariable logistic regression showed that attendance at discussions or presentations on MSCs in the past 2 years (p&amp;lt;0.0001) and seeing more patients with CD per year (p=0.0002) were associated with increased awareness of the therapy. Conclusion In this study, the majority of physicians demonstrated interest and willingness to use MSCs in clinical practice. However, the survey showed a perceived lack of knowledge of what MSCs are and how they work in patients with CPF in CD. This may explain physicians’ concerns about using MSCs in this indication. Increased communication and education regarding MSCs are required to alleviate physicians’ concerns and increase the uptake of this therapy in routine practice. Sponsor: Takeda Pharmaceuticals USA, Inc.

Analisis Pengaruh Perkembangan Sektor Keuangan Terhadap Industrialisasi pada Negara Industri Baru di Asia Pasifik

This study examines the influences of financial development on the industrialization by combining cross section data for the five newly industrialized countries in Asia Pacific with time series data from the period 2000 to 2019. The results by using fixed effect model showed that: (1) financial depth has a negative and significant on the industrialization in newly industrialized countries in Asia Pacific; (2) financial efficiency has a positif and significant on the industrialization in newly industrialized countries in Asia Pacific; (4) financial stability has a negative and significant on the industrialization in newly industrialized countries in Asia Pacific; and (5) financial depth, financial efficiency and trade openness and foreign direct investment inflow have significantly affected the industrialization in newly industrialized countries in Asia Pacific.

PENGARUH SUKU BUNGA, KURS RILL DAN PERTUMBUHAN EKONOMI TERHADAP YIELD OBLIGASI PEMERINTAH : LOWER MIDDLE INCOME COUNTRIES DI ASIA PASIFIK

This study explains the influence of monetary policy interest rates, real exchange rates and economic growth on government bond yields on Lower Middle Income Countries in Asia Pacific. This study combines cross section data in 5 countries with time series from 2007-2018, with the Panel Regression method and the Random Effect model selection test. The results show that: (1) Monetary Policy Interest Rates has a positive and significant effect on government bond yields on Lower Middle Income Countries in Asia Pacific, (2) The real exchange rate have a negative and significant effect on government bond yields for Lower Middle Income Countries in Asia Pacific. , (3) Economic growth has a negative and significant effect on government bond yields on Lower Middle Income Countries in Asia Pacific.

PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Background:The pivotal FIRST trial, the largest study conducted in transplant‐ineligible (TNE) patients (pts) with newly diagnosed multiple myeloma (NDMM), examined lenalidomide plus low‐dose dexamethasone until disease progression (Rd continuous), Rd for 18 cycles (Rd18), and melphalan, prednisone, and thalidomide (MPT). The study, conducted in 18 countries in Europe, North America, and Asia Pacific, demonstrated that Rd continuous significantly improved progression‐free survival (PFS) vs MPT (median 26.0 vs 21.9 mos; HR, 0.69; 95% CI, 0.59‐0.79; P &lt; .00001). PFS was similarly extended for Rd continuous vs Rd18 (median 21.0 mos; HR, 0.70; 95% CI, 0.60‐0.81). Furthermore, median overall survival (OS) was significantly longer with Rd continuous vs MPT (median 59.1 vs 49.1 mos; HR, 0.78; 95% CI, 0.67‐0.92; P = .0023). These results support the use of frontline oral, alkylator‐free continuous therapy for TNE NDMM pts and established Rd continuous as a standard of care as reflected by clinical guidelines in Canada, the US, and Europe.Aims:To report outcomes in the subset of patients from Canada and the US.MethodsPts with TNE NDMM were randomized 1:1:1 to Rd continuous (with lenalidomide given on days 1‐21 of 28‐day cycles until disease progression), Rd18 (with lenalidomide given on days 1‐21 of eighteen 28‐day cycles), or MPT (twelve 42‐day cycles). Rd18 and MPT were both 72 weeks in duration. Stratification factors included country and Rd continuous vs MPT was the primary comparison. The primary endpoint was PFS and secondary endpoints included OS, time to next therapy (TTNT) and safety. Time from randomization to second progression or death (PFS2) was an exploratory analysis. Response assessment used for PFS and PFS2 analysis was determined by investigators based on International Myeloma Working Group criteria. Data is presented as of the January 21, 2016 cutoff used for the final OS analysis.Results:A total of 312 pts from Canada (n = 252) and the US (n = 60) were enrolled (104 in each arm). Consistent with results from the intent‐to‐treat (ITT) analysis, the Canada/US subgroup also demonstrated a significant improvement in PFS with Rd continuous vs MPT (median 29.3 vs 20.2 mos; HR, 0.69; 95% CI, 0.49‐0.97; P = .03326) and an improvement vs Rd18 (median 21.9 mos; HR, 0.72; 95% CI, 0.51‐1.02; Table). Median OS was 56.9 vs 46.8 mos for Rd continuous vs MPT (HR, 0.77; 95% CI, 0.53‐1.11; P = .15346). Median PFS2 was longer for Rd continuous vs MPT (median 39.3 vs 35.1 mos; HR, 0.69; 95% CI 0.50‐0.95) as was TTNT (median 39.1 vs 24.6 mos; HR, 0.54; 95% CI, 0.37‐0.78). Additional details, including safety data, will be presented at the meeting.Summary/Conclusion:In the Canada/US subpopulation of pts from FIRST, Rd continuous extended median PFS by 9 mos vs MPT and &gt; 7 mos vs Rd18. Rd continuous also delayed median TTNT &gt; 14 mos and resulted in a longer PFS2 vs MPT, suggesting that the benefit from frontline Rd continuous is maintained at relapse. These results are consistent with that from the ITT population confirming the advantage of Rd continuous vs MPT in the Canada/US subgroup and supporting the role of Rd continuous as a standard of care for TNE pts with NDMM. The efficacy observed with Rd continuous raises the question on the role of immunostimulatory effects by the immunomodulatory agents in NDMM.image

Advanced ERP Application for Marine Transportation Industry in the South Asia Pacific Country; a Case Study

Marine transportation industry is one of the most vital activities in the world. Demand to provide effective and efficient inter-regional connectivity within the marine transportation framework will be a common agenda in some areas. South Asia Pacific region has a member country of more than 14 countries. With the region’s economic growth of about 5.3 percent, compared to the world average of 3.2 percent, because it is the most safe area compared to other regions (Antara, 2016). Almost 70% of total world trade takes place among countries in Asia Pacific. In this study, we try to focus on comparative analysis of IT support system to support the operation of marine transportation services in 3 countries namely Indonesia, Malaysia and USA. Some port systems in the archipelagic country particularly the South Asia Pacific region have adopted approaches such as the ERP system, but are still partial. Each part of the port management creates its own information system, and links it to every organization’s website. Utilizing existing ERP systems, will be key in designing new frameworks with IOT concepts. With the development of IOT techniques and major investments in marine transportation systems in the Asia Pacific region, intelligent transportation will be able to improve the effectiveness and efficiency of marine and port transportation services processes. The technology of the Internet of Things will enable the development of transportation systems to be more intelligent, safe, harmonious, and energy efficient.

Global Dispersant Approvals in Asia Pacific – Current Status and On Going Challenges

ABSTRACT Following the Macondo Incident, the international oil and gas industry spent significant time and effort analyzing lessons learned and implementing key projects to ensure that critical response and preparedness issues that were identified are addressed to improve response capabilities. The Global Dispersant Stockpile (GDS) was established as part of a post-Macondo Joint Industry Project through Oil Spill Response Limited (OSRL), recognizing that delivery of sufficient quantities of dispersant is a key element for a successful dispersant operation, especially during the initial phases of a large scale response to an event such as a subsea well blowout. Taking into account the global approval status and proven effectiveness on a range of crude oils, three key oil dispersants, Finasol® OSR 52 (Total), Corexit® EC9500A (Nalco) and Slickgone® NS (Dasic) were selected for the Global Dispersant Stockpile. A total of 5,000 m3 of these dispersants are now stored and ready to be deployed from five strategically positioned global locations. For example, sizable volumes of two of these products (total volume = 700 m3) are located at OSRL’s response base in Singapore, which can be quickly mobilized to support a response in the Asia Pacific region. An ongoing effort associated with the management of the GDS is to enable the pre-approval of at least one of the three products for countries in the region where spill response may be required. At present, this is not the case in the region for a variety of reasons, e.g., toxicity concerns and biodegradation processes of dispersed oil. A particularly cautious approach by regulatory authorities following the Macondo incident, coupled with a number of other specific regional concerns, has exacerbated the issue of obtaining and maintaining dispersant approvals in the region. The aim of this paper is to identify and discuss the existing regulatory framework governing the dispersant product approval process and dispersant use authorization for countries in Asia Pacific. The paper will detail the present status of regulations related to dispersant use for a number of countries in the region, the potential challenges associated with achieving permissions in countries with no regulations and a discussion of strategies to address identified obstacles. Additionally the activities that are being undertaken to expand regulatory approvals will also be addressed. It is anticipated that a greater understanding of the reasoning behind the GDS will facilitate a positive regulatory perspective and the potential for dispersant pre-approval in the region.

All-cause mortality in HIV-positive adults starting combination antiretroviral therapy: correcting for loss to follow-up.

To estimate mortality in HIV-positive patients starting combination antiretroviral therapy (ART) and to discuss different approaches to calculating correction factors to account for loss to follow-up. A total of 222 096 adult HIV-positive patients who started ART 2009-2014 in clinics participating in the International epidemiology Databases to Evaluate AIDS collaboration in 43 countries in sub-Saharan Africa, Asia Pacific, Latin America, and North America were included. To allow for underascertainment of deaths due to loss to follow-up, two correction factors (one for the period 0-6 months on ART and one for later periods) or 168 correction factors (combinations of two sexes, three time periods after ART initiation, four age groups, and seven CD4 groups) based on tracing patients lost in Kenya and data linkages in South Africa were applied. Corrected mortality rates were compared with a worst case scenario assuming all patients lost to follow-up had died. Loss to follow-up differed between regions; rates were lowest in central Africa and highest in east Africa. Compared with using two correction factors (1.64 for the initial ART period and 2.19 for later), applying 168 correction factors (range 1.03-4.75) more often resulted in implausible mortality rates that exceeded the worst case scenario. Corrected mortality rates varied widely, ranging from 0.2 per 100 person-years to 54 per 100 person-years depending on region and covariates. Implausible rates were less common with the simpler approach based on two correction factors. The corrected mortality rates will be useful to international agencies, national programmes, and modellers.

Abstract P4-13-09: Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study

Abstract Background BOLERO-2 phase III trial established the efficacy of everolimus (EVE) plus exemestane (EXE) for the treatment of postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer (aBC). However, in this study only a minority (&amp;lt;10%) of patients were recruited from African and Asia Pacific countries. Considering the potential effects of ethnic and cultural differences on treatment effectiveness, it remains compelling to confirm the safety and efficacy profile of EVE+EXE in these populations. Methods EVEREXES is an open-label phase IIIb, single arm, multi-center trial, which from March 2013 to October 2014 enrolled 232 post-menopausal, HR-positive and HER2-negative, aBC patients previously treated with aromatase inhibitors, across 13 countries in Asia Pacific, Middle East, North and South Africa, with a significant majority of patients being of Asian ethnicity (196, 84.5%). Its primary objective was to investigate the safety and tolerability profile of EVE+EXE. Secondary objectives were the evaluation of efficacy (assessed by PFS, ORR, and CBR based on RECIST 1.1 criteria) and change in ECOG performance status. Results At data cut off of 31st of January 2015, at a median follow up of 11.7 months, median PFS for the ITT population was 9.5 months [9.2-11.6 months], based on local assessment, with the observation of 1 (0.4%) CR and 35 (15.4%) PR. Regarding safety and tolerability, a majority (81.1%) of grade (G) 1/2 adverse events (AEs) was reported. In particular, the following pattern was observed in terms of % of patients who developed G1/G2/G3 mTOR-inhibition induced AEs: stomatitis (36.1, 13.7, 10.6), rash (21.6/6.2/0), fatigue (10.6, 4.4, 2.2), hyperglycemia (6.2, 11.5, 7.0), weight decrease (7.5, 7, 0.9), pneumonitis (5.7, 7, 0.9). No Grade 4 AEs related to EVE+EXE treatment were observed, with exception of one case of non infectious pneumonitis (0.4%). Median dose intensity of everolimus was 9.2 mg/day. Conclusions Efficacy and safety results from EVEREXES trial further confirm the role of EVE+EXE for the treatment of HR+/Her2- advanced BC patients in Eastern countries. Results were consistent with data previously reported in BOLERO-2 trial. Citation Format: Im Y-H, Uslu R, Lee KS, Nagarkar R, Sohn J, Sevinc A, Altundag K, Chang Y-C, Abdel-Razeq H, Im S-A, Jeong J, Park HY, Arpornwirat W, Bastick P, Le TH, Ocak Arikan O, Xue HL, Canatar A, Valenti R, Kim S-B. Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-09.

--------------- (Evolution of Approaches to Competitive Advantages in the Most Developed Countries in Asia-Pacific)

Монография посвящена исследованию конкурентных преимуществ стран АТР. Представлены факторы и модели для оценки конкурентоспособности. Специальное внимание уделяется исследованию конкурентных преимуществ Австралии. Книга предназначена для научных сотрудников, преподавателей, аспирантов, студентов, изучающих конкурентоспособность национальных экономик. The monograph is devoted to the study of the competitive advantages of the APR countries. Presented factors and models to assess competitiveness. Special attention is paid to the study of competitive advantage in Australia. The book is intended for researchers, teachers, graduate students studying the competitiveness of national economies.

Clinical outcomes in treatment of chronic total occlusions with the XIENCE V everolimus-eluting stent system in real-world patients: one-year pooled results from the XIENCE V USA and SPIRIT V studies

Purpose: Recanalization of chronic total occlusion (CTO) remains a major challenge in interventional cardiology. The objective of this pooled analysis was to evaluate the safety and effectiveness of XIENCE V when treating CTO lesions. Methods: Both XIENCE V USA and SPIRIT V are large, prospective, multicenter, post-approval, real-world studies conducted in the US and 29 countries in Europe and Asia Pacific. Baseline and 1-year clinical outcomes were compared between patients with and without treatment of at least 1 CTO lesion during the index procedure. Results: Baseline characteristics and clinical outcomes are summarized in the table. View this table: Table 1. Clinical results in patients with and without CTO lesions treated Conclusions: The one-year stent thrombosis rate and other clinical event rates were low in the CTO cohort and were comparable to those of the non-CTO cohort despite an increase in lesion complexity. These results demonstrate the safety and effectiveness of XIENCE V in real-world CTO treatment. However, despite the large population enrolled in both studies, the sample size of the CTO cohort was relatively small. Therefore, results obtained from this pooled analysis are yet to be confirmed in a large, prospective, randomized study.

Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry

BackgroundLimited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide perspective. The aim of this study was to describe the baseline characteristics and initial therapeutic management of patients with non-valvular atrial fibrillation across the spectrum of sites at which these patients are treated.Methods and FindingsThe Global Anticoagulant Registry in the FIELD (GARFIELD) is an observational study of patients newly diagnosed with non-valvular atrial fibrillation. Enrollment into Cohort 1 (of 5) took place between December 2009 and October 2011 at 540 sites in 19 countries in Europe, Asia-Pacific, Central/South America, and Canada. Investigator sites are representative of the distribution of atrial fibrillation care settings in each country. Cohort 1 comprised 10,614 adults (≥18 years) diagnosed with non-valvular atrial fibrillation within the previous 6 weeks, with ≥1 investigator-defined stroke risk factor (not limited to those in existing risk-stratification schemes), and regardless of therapy. Data collected at baseline included demographics, medical history, care setting, nature of atrial fibrillation, and treatments initiated at diagnosis. The mean (SD) age of the population was 70.2 (11.2) years; 43.2% were women. Mean±SD CHADS2 score was 1.9±1.2, and 57.2% had a score ≥2. Mean CHA2DS2-VASc score was 3.2±1.6, and 8,957 (84.4%) had a score ≥2. Overall, 38.0% of patients with a CHADS2 score ≥2 did not receive anticoagulant therapy, whereas 42.5% of those at low risk (score 0) received anticoagulant therapy.ConclusionsThese contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke.Trial RegistrationClinicalTrials.gov TRI08888

Characterisation of Patients Receiving Moxifloxacin for Acute Bacterial Rhinosinusitis in Clinical Practice: Results from an International, Observational Cohort Study

We conducted a prospective, non-controlled, multi-centre Phase IV observational cohort study of patients with acute bacterial rhinosinusitis who were treated with moxifloxacin in clinical practice in 19 countries in Asia Pacific, Europe and the Middle East. With the data collected we evaluated the presentation and course of the current disease episode, particularly in terms of the principal clinical signs and symptoms of acute rhinosinusitis and diagnostic procedures. A final assessment of moxifloxacin therapy was made to evaluate the impact of the sinusitis episode on activities of daily life and on sleep disturbance, and to evaluate the clinical outcome of treatment. A total of 7,090 patients were enrolled, of whom 3909 (57.6%) were included in the valid for clinical outcome and safety population. Regional differences were observed in the main symptoms of acute rhinosinusitis and, according to several characteristics, disease episodes appeared to be more severe in patients in Europe than in the Asia Pacific or Middle East regions. The sinusitis episode impacted on daily living for mean (SD) periods of 3.6 (3.2), 4.6 (3.9) and 3.1 (3.0) days and disturbed sleep for 3.6 (3.2), 4.6 (3.9) and 3.1 (3.0) nights in the Asia Pacific, Europe and Middle East regions, respectively. With moxifloxacin treatment, the mean (SD) time to improvement of symptoms was 3.0 (1.5), 3.4 (1.6) and 3.2 (1.5) days, and the time to resolution of symptoms was 4.8 (2.6) days, 5.7 (2.4) days and 5.5 (2.5) days, in the Asia Pacific, Europe and Middle East regions, respectively. In conclusion, acute rhinosinusitis remains a substantial health burden with significant impact on patients’ quality of life, and there are differences between global regions in the clinical presentation, diagnosis and clinical course of disease episodes. Moxifloxacin was an effective and well-tolerated treatment option in the overall population. Registration: ClinicalTrials.gov Identifier: NCT00930488